(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP) announced Monday that its interventional psychiatry network HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical following ...

Jeremy Shefner, M.D., Ph.D., Chair of the Department of Neurology and Senior Vice President at the Barrow Neurological Institute, will present new, compelling data from the Phase 2b trial of ...

In a report released today, Catherine Novack from JonesTrading maintained a Buy rating on Aldeyra Therapeutics (ALDX – Research Report), with a price target of $10.00. The company’s shares ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ...

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual ...

“Our first reaction is one of relief. That said, we remain very vigilant and concerned about the future,” said David Gering from Pharma.be. He added that the American market represents a signi ...

Jeremy Shefner, M.D., Ph.D., Chair of the Department of Neurology and Senior Vice President at the Barrow Neurological Institute, will present new, compelling data from the Phase 2b trial of PrimeC, ...

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual ...

This has reignited investor interest and the field is now ripe for partnerships with the pharma industry. DTx have been a transformative force in healthcare, providing an alternative evidence ...

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United ...

Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.